Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Sign Up to like & getrecommendations! Published in 2021 at "Diabetologia"
DOI: 10.1007/s00125-021-05508-1
Abstract: Concerns have been raised regarding a potential association of use of the incretin-based drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1)-receptor agonists with risk of cholangiocarcinoma. We examined this association in nationwide data… read more here.
Keywords: dpp4 inhibitors; receptor agonists; cholangiocarcinoma; glp receptor ... See more keywords
Hypertension and risk of cholangiocarcinoma: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Translational cancer research"
DOI: 10.21037/21315
Abstract: Background: Hypertension has been demonstrated to enhance the risk of cholangiocarcinoma (CCC) by several researches, which, however, still remains controversial. To this end, a systematic review and meta-analysis was performed to further investigate the association… read more here.
Keywords: risk; review meta; analysis; systematic review ... See more keywords